Results 11 to 20 of about 8,934 (195)

Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT [PDF]

Clinical Cancer Research, 2021
Abstract Purpose: To assess the response to pexidartinib treatment in six cohorts of adult patients with advanced, incurable solid tumors associated with colony-stimulating factor 1 receptor (CSF1R) and/or KIT proto-oncogene receptor tyrosine kinase activity.
William D. Tap, Arun S. Singh, Stephen Patrick Anthony, Mike Sterba, Chao Zhang, John H. Healey, Bartosz Chmielowski, Allen Lee Cohn, Geoffrey I. Shapiro, Vicki L. Keedy, Zev A. Wainberg, Igor Puzanov, Gregory M. Cote, Andrew J. Wagner, Fadi Braiteh, Eric Sherman, Henry H. Hsu, Charles Peterfy, Heather L. Gelhorn, Xin Ye, Paul Severson, Brian L. West, Paul S. Lin, Sandra Tong-Starksen   +23 more
openaire   +6 more sources

TGCT of the shoulder - a case series and literature review. [PDF]

Arch Orthop Trauma Surg
Abstract Introduction Tenosynovial giant cell tumor (TGCT), also known as pigmented villonodular synovitis (PVNS), involving the shoulder is extremely rare and can present with a challenging clinical course. Due to the complex anatomy of the shoulder, both diagnosis and treatment are demanding.
Stadelmeier J, Bijeljac F, Klein A, Winden F, Reidler P, Dürr HR.   +5 more
europepmc   +4 more sources

Updates on the Treatment of Tenosynovial Giant Cell Tumor

Hematology/Oncology and Stem Cell Therapy, 2023
Tenosynovial giant cell tumor (TGCT) is a rare inflammatory disorder affecting the joint synovium, bursae, and tendon sheaths that causes non-specific and often insidious joint discomfort.
Abigail S. Chan, Vatsala Katiyar, Paul Dy, Vikas Singh   +3 more
doaj   +2 more sources

Surgical management of 144 diffuse‐type TGCT patients in a single institution: A 20‐year cohort study [PDF]

Journal of Surgical Oncology, 2022
AbstractBackground and ObjectivesSurgery is the mainstay of treatment for tenosynovial giant cell tumors (TGCTs). However, achieving a cure through surgery alone remains challenging, especially for the diffuse‐type (D‐TGCT).MethodsOur goal was to describe the surgical management of patients with D‐TGCT related to large joints, treated between 2000 and ...
Geert Spierenburg, Lizz van der Heijden, Monique J. L. Mastboom, Kirsten van Langevelde, Robert J. P. van der Wal, Hans Gelderblom, Michiel A. J. van de Sande   +6 more
openaire   +4 more sources

Higher incidence rates than previously known in tenosynovial giant cell tumors: A nationwide study in The Netherlands

Acta Orthopaedica, 2017
Background and purpose — Tenosynovial giant cell tumors (TGCT) are rare, benign tumors, arising in synovial lining of joints, tendon sheaths, or bursae. 2 types are distinguished: localized, either digits or extremity, and diffuse lesions.
Monique J L Mastboom, Floortje G M Verspoor, Arjan J Verschoor, Daniël Uittenbogaard, Banne Nemeth, Walter J B Mastboom, Judith V M G Bovée, P D Sander Dijkstra, H W Bart Schreuder, Hans Gelderblom, Michiel A J Van de Sande, TGCT study group   +11 more
doaj   +2 more sources

Tenosynovial giant cell tumours of the foot and ankle: a retrospective single centre experience with surgical treatment of 34 cases

BMC Cancer
Background Tenosynovial giant cell tumour (TGCT) is one of the most prevalent soft tissue tumours of the foot and ankle. Although typically benign, it can exhibit locally aggressive behaviour.
Christian Scheele, Norbert Harrasser, Simone Beischl, Dietmar Dammerer, Ulrich Lenze, Carolin Knebel, Rüdiger von Eisenhart-Rothe, Florian Lenze   +7 more
doaj   +2 more sources

Multi-omics highlights the impacts of cryptorchidism history on immune microenvironment variation in TGCT

Discover Oncology
The unique altered biological processes in testicular germ cell tumor (TGCT) patients with cryptorchidism history require further investigation and the accumulation of tumor-related features in cryptorchidism remains unclear.We analyzed transcriptome and DNA methylation (DNAme) data from normal, undescended testis (UDT), and TGCT samples.
Li, Gao, Zhao, Yaqian, Wang, Mengtong, Fan, Hailang, Chen, Yuanhao, Zhang, Haikun, Zhao, Yu, Zhang, Feifan, Sun, Lanlan, Ma, Yina, Wei, Chenyang, Schrodi, Steven J., Zhang, Dake, Zhang, Xin   +13 more
openaire   +4 more sources

Supplementary Data from Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT

, 2022
Supplementary Data from Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in ...
Stephen Patrick Anthony (11959735), Fadi Braiteh (14998773), William D. Tap (15017801), Gregory M. Cote (15036672), Brian L. West (8863253), John H. Healey (15036663), Henry H. Hsu (11959749), Sandra Tong-Starksen (11959746), Paul Severson (6868589), Mike Sterba (11959744), Allen Lee Cohn (11959738), Igor Puzanov (5198039), Vicki L. Keedy (15036669), Bartosz Chmielowski (15036666), Heather L. Gelhorn (12523522), Arun S. Singh (15036660), Zev A. Wainberg (9552988), Eric Sherman (3913357), Paul S. Lin (15036675), Geoffrey I. Shapiro (14961801), Chao Zhang (51048), Charles Peterfy (674120), Xin Ye (208347), Andrew J. Wagner (15021018)   +23 more
core   +6 more sources

Diffuse-Type Tenosynovial Giant Cell Tumor of the Hip With Acetabular Bone Involvement: A Case Report With Radiologic-Pathologic Correlation. [PDF]

Cancer Rep (Hoboken)
ABSTRACT Background Diffuse‐type tenosynovial giant cell tumor (D‐TGCT) is an uncommon synovial neoplasm. Hip involvement is rare and may be difficult to recognize because symptoms are nonspecific and osseous erosion can mimic more aggressive infectious, inflammatory, or neoplastic processes.
Quanbing W, Huanhuan X, Xing Z, Tao Y, Jun Z, Lei Z, Kai L, Lei L, Feng A, Wei Y.   +9 more
europepmc   +2 more sources

Vimseltinib for patients with tenosynovial giant cell tumor: A multicenter, open-label, phase 2 trial. [PDF]

Cancer
Abstract Background Tenosynovial giant cell tumor (TGCT) is a locally aggressive neoplasm caused by dysregulation of the colony‐stimulating factor 1 (CSF1) gene. Patients report substantial pain, stiffness, and declining physical function; those whose disease is not amenable to surgery require systemic therapy.
Stacchiotti S, Blay JY, Rutkowski P, Gelderblom H, Falcón A, Le Cesne A, Desai J, Palmerini E, Serrano C, Ganjoo KN, D'Amato GZ, Ryan CW, Wilky BA, Ferraresi V, Saleh R, Ravi V, Razak AA, Herráez AC, Ahmed M, Bernthal NM, van de Sande M, Brahmi M, Szostakowski B, Sen J, Zeringo NA, Harrow B, Narasimhan S, Saunders A, Sharma MG, Sherman ML, Wagner AJ, Tap WD.   +31 more
europepmc   +2 more sources